Literature DB >> 27319408

Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community - The Hisayama Study.

Keita Takae1, Masaharu Nagata, Jun Hata, Naoko Mukai, Yoichiro Hirakawa, Daigo Yoshida, Hiro Kishimoto, Kazuhiko Tsuruya, Takanari Kitazono, Yutaka Kiyohara, Toshiharu Ninomiya.   

Abstract

BACKGROUND: Growing evidence suggests that high serum uric acid (SUA) levels are causally related to increased risk of chronic kidney disease (CKD). However, few studies have investigated the influence of elevated SUA levels on the incidence of kidney dysfunction and albuminuria separately in community-based populations. METHODS AND 
RESULTS: A total of 2,059 community-dwelling Japanese subjects aged ≥40 years without CKD were followed for 5 years. CKD was defined as kidney dysfunction (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) or albuminuria (urine albumin-creatinine ratio ≥30 mg/g). The odds ratio (OR) for the development of CKD was estimated according to quartiles of SUA (≤4.0, 4.1-4.9, 5.0-5.8, and ≥5.9 mg/dl). During the follow-up, 396 subjects developed CKD, of whom 125 had kidney dysfunction and 312 had albuminuria. The multivariable-adjusted risk of developing CKD increased with higher SUA levels (OR 1.00 [reference] for ≤4.0, 1.21 [95% confidence interval, 0.84-1.74] for 4.1-4.9, 1.47 [1.01-2.17] for 5.0-5.8, and 2.10 [1.37-3.23] for SUA ≥5.9 mg/dl, respectively). Similarly, there were positive associations between SUA level and the adjusted risk of developing kidney dysfunction (OR 1.00 [reference], 2.30 [1.10-4.82], 2.81 [1.34-5.88], and 3.73 [1.65-8.44]) and albuminuria (1.00 [reference], 1.12 [0.76-1.65], 1.35 [0.90-2.03], and 1.81 [1.14-2.87], respectively).
CONCLUSIONS: Higher SUA levels were a significant risk factor for the development of both kidney dysfunction and albuminuria in a general Japanese population. (Circ J 2016; 80: 1857-1862).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27319408     DOI: 10.1253/circj.CJ-16-0030

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  18 in total

1.  Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m2 and negative proteinuria.

Authors:  Fangfang Zhou; Geping Yu; Guoyu Wang; Yunzi Liu; Liwen Zhang; Weiming Wang; Nan Chen
Journal:  Clin Exp Nephrol       Date:  2019-02-08       Impact factor: 2.801

2.  Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function.

Authors:  Masanari Kuwabara; Petter Bjornstad; Ichiro Hisatome; Koichiro Niwa; Carlos A Roncal-Jimenez; Ana Andres-Hernando; Thomas Jensen; Tamara Milagres; Yuka Sato; Gabriela Garcia; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson
Journal:  Am J Nephrol       Date:  2017-03-11       Impact factor: 3.754

3.  Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial.

Authors:  Masato Kasahara; Yoshihiro Kuwabara; Toshiki Moriyama; Kazuaki Tanabe; Noriko Satoh-Asahara; Tomohiro Katsuya; Shinya Hiramitsu; Hidetaka Shimada; Tosiya Sato; Yoshihiko Saito; Takahiko Nakagawa
Journal:  Clin Exp Nephrol       Date:  2019-11-15       Impact factor: 2.801

4.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

5.  Serum Uric Acid Levels and Nephrosclerosis in a Population-Based Autopsy Study: The Hisayama Study.

Authors:  Kenji Maki; Jun Hata; Satoko Sakata; Emi Oishi; Yoshihiko Furuta; Toshiaki Nakano; Yoshinao Oda; Takanari Kitazono; Toshiharu Ninomiya
Journal:  Am J Nephrol       Date:  2022-02-01       Impact factor: 3.754

6.  Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.

Authors:  Yasuo Terauchi; Masahiro Tamura; Masayuki Senda; Ryoji Gunji; Kohei Kaku
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

Review 7.  Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2016-12-03       Impact factor: 10.479

8.  Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.

Authors:  Na Liu; Liuqing Xu; Yingfeng Shi; Lu Fang; Hongwei Gu; Hongrui Wang; Xiaoqiang Ding; Shougang Zhuang
Journal:  Oncotarget       Date:  2017-05-16

9.  Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.

Authors:  Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Koichi Node
Journal:  Drugs R D       Date:  2017-03

10.  Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study.

Authors:  Stanford E Mwasongwe; Tibor Fülöp; Ronit Katz; Solomon K Musani; Mario Sims; Adolfo Correa; Michael F Flessner; Bessie A Young
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-16       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.